Comparative analysis of DNA repair gene expression in euploid and aneuploid human blastocysts

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260603009

Enrollment

Registered

2026-06-03

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility Assisted Reproductive Technology Outcome Reproductive Outcome Infertility Assisted Reproductive Techniques In Vitro Fertilization Embryo Implantation Blastocyst Trophectoderm Preimplantation Genetic Testing

Interventions

Blastocysts diagnosed as euploid by preimplantation genetic testing for aneuploidy (PGT-A). Trophectoderm cells obtained during routine embryo biopsy will be analyzed for DNA repair gene expression u

Screening,Screening

Euploid Blastocyst Group,Aneuploid Blastocyst Group

Eligibility

Sex/Gender

Female

Age

18 Years to 49 Years

Inclusion criteria

Inclusion criteria: Women diagnosed with infertility who undergo in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment and have blastocysts undergoing preimplantation genetic testing for aneuploidy (PGT-A). Women undergoing controlled ovarian stimulation using a GnRH antagonist protocol, consisting of recombinant follicle-stimulating hormone (rFSH) for ovarian stimulation, GnRH antagonist for prevention of premature ovulation, and dual triggering with GnRH agonist and recombinant human chorionic gonadotropin (hCG) for final oocyte maturation

Exclusion criteria

Exclusion criteria: Women with uterine cavity abnormalities that may affect implantation or pregnancy outcomes, including endometrial polyps or submucosal uterine fibroids. Women diagnosed with conditions known to influence gene expression profiles, including endometriosis or polycystic ovary syndrome (PCOS). Women with a body mass index (BMI) greater than or equal to 30. Women whose embryos fail to develop to the blastocyst stage. Embryos with an insufficient number of trophectoderm cells available for gene expression analysis.

Design outcomes

Primary

Measure	Time frame
Differential expression of DNA repair-related genes between euploid and aneuploid blastocysts Relative gene expression levels measured by RNA sequencing (RNA-seq) and validated by RT-qPCR. Expression reported as fold change and delta-delta Ct values. Relative gene expression levels measured by RNA sequencing (RNA-seq) and validated by RT-qPCR. Expression reported as fold change and delta-delta Ct values	—

Measure

Time frame

Differential expression of DNA repair-related genes between euploid and aneuploid blastocysts Relative gene expression levels measured by RNA sequencing (RNA-seq) and validated by RT-qPCR. Expression reported as fold change and delta-delta Ct values. Relative gene expression levels measured by RNA sequencing (RNA-seq) and validated by RT-qPCR. Expression reported as fold change and delta-delta Ct values

—

Secondary

Measure	Time frame
Implantation rate 14 days after embryo transfer Presence of serum beta-hCG following transfer of a single euploid embryo,Clinical pregnancy rate 6 weeks of gestation Presence of intrauterine gestational sac with fetal heartbeat detected by transvaginal ultrasonography,Miscarriage rate Up to 20 weeks of gestation Pregnancy loss after confirmation of clinical pregnancy	—

Countries

Thailand

Contacts

Public ContactKasidech Tanjaturon

KCMH

boatkasidech@gmail.com0654741595

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026